Broadly neutralizing influenza hemagglutinin stem-directed antibodies
US Application 63/605,374
Filed on 2023-12-01
Filed on 2023-12-01
SINGLE-DOMAIN AND BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE
US Application 63/558,539
Filed on 2024-02-27
Filed on 2024-02-27
Broadly Neutralizing Antibodies Against SARS-CoV-2 and SARS-CoV Variants
US Application 63/613,327
Filed on 2023-12-21
Filed on 2023-12-21
Self-assembling Nanoparticles Based On Amphiphilic Peptides
India
202317059300
Filed on 2023-09-04
202317059300
Filed on 2023-09-04
HUMAN MONOCLONAL ANTIBODIES THAT TARGET TERMINAL ALPHA-GAL MOIETIES ON VECTOR-BORNE PATHOGENS AND UNRESECTABLE SOLID TUMORS
US Application 63/647,859
Filed on 2024-05-15
Filed on 2024-05-15
NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE
US Application 63/617,717
Filed on 2024-01-04
Filed on 2024-01-04
EPSTEIN-BARR VIRUS VACCINES
US Application 18/659,639
Filed on 2024-05-09
Filed on 2024-05-09
METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION
Israel
250743
Filed on 2017-02-23
250743
Filed on 2017-02-23
MenAfriVac, Low-Cost Meningitis Vaccine, Wins LES Deals of Distinction Award
The 2014 Deals of Distinction Award from the LES Industry-University-Government Interface Sector (IUGI) went to the U. S. Food and Drug Administration (FDA), National Institutes of Health (NIH), PATH, and the Serum Institute of India (SII) for MenAfriVac, a low-cost meningitis vaccine designed for use in sub-Saharan Africa.